





# BMJ Open Core socioDemographic data variables in ICU Trials (CoDe-IT): a protocol for generating core data variables using a Delphi consensus process

Karla D Krewulak <sup>1</sup>, Fatima Sheikh <sup>2</sup>, Alya Heirali,<sup>1</sup> John C Marshall,<sup>3</sup> Karen E A Burns,<sup>4,5</sup> Scotty Kupsch,<sup>1</sup> Christina Maratta,<sup>6</sup> Srinivas Murthy,<sup>7</sup> Katie O'Hearn <sup>8</sup>, Kristine Russell,<sup>1</sup> Sangeeta Mehta,<sup>4,9</sup> Kirsten Fiest <sup>1,10</sup>

**To cite:** Krewulak KD, Sheikh F, Heirali A, *et al.* Core socioDemographic data variables in ICU Trials (CoDe-IT): a protocol for generating core data variables using a Delphi consensus process. *BMJ Open* 2024;**14**:e082912. doi:10.1136/bmjopen-2023-082912

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2023-082912>).

KDK and FS contributed equally.

Received 06 December 2023  
Accepted 28 June 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Kirsten Fiest;  
kmfiest@ucalgary.ca

## ABSTRACT

**Introduction** Sociodemographic variables influence health outcomes, either directly (ie, gender identity) or indirectly (eg, structural/systemic racism based on ethnoracial group). Identification of how sociodemographic variables can impact the health of critically ill adults is important to guide care and research design for this population. However, despite the growing recognition of the importance of collecting sociodemographic measures that influence health outcomes, insufficient and inconsistent data collection of sociodemographic variables persists in critical care studies. We aim to develop a set of core data variables (CoDaV) for social determinants of health specific to studies involving critically ill adults.

**Methods and analysis** We will conduct a scoping review to generate a list of possible sociodemographic measures to be used for round 1 of the modified Delphi processes. We will engage relevant knowledge users (previous intensive care unit patients and family members, critical care researchers, critical care clinicians and research co-ordinators) to participate in the modified Delphi consensus survey to identify the CoDaV. A final consensus meeting will be held with knowledge user representatives to discuss the final CoDaV, how each sociodemographic variable will be collected (eg, level of granularity) and how to disseminate the CoDaV for use in critical care studies.

**Ethics and dissemination** The University of Calgary conjoint health research ethics board has approved this study protocol (REB22-1648).

## INTRODUCTION

Research shows that sociodemographic variables such as gender identity, race and ethnicity and socioeconomic status can influence health outcomes.<sup>1 2</sup> There is a lack of consistent reporting of sociodemographic variables in adult intensive care unit (ICU) studies. To evaluate the impact of sociodemographic variables on health outcomes of critically ill adults, key knowledge users must inform a set of core data variables (CoDaV) of sociodemographic measures that can influence health outcomes. Marginalised

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ We engaged a diverse group of knowledge users from study inception.
- ⇒ Patient and family partners with lived intensive care unit (ICU) experience and from equity-deserving groups were involved in the design of this research.
- ⇒ Multiple data sources will be used to inform statements that will be rated and ranked during the modified Delphi consensus process.
- ⇒ The findings from this study may not be generalisable to other contexts outside of the ICU or outside of Canada.

groups in critical care medicine have worse health outcomes.<sup>3 4</sup> Moreover, insufficient recruitment and retention of marginalised populations in clinical trials<sup>5-8</sup> limit evidence-based findings to improve quality of care and outcomes for these populations. Understanding social determinants of health (SDoH) across all critical care clinical research requires representation of marginalised populations in clinical trials, as well as robust and standardised data collection of sociodemographic variables.

Despite the growing recognition of the importance of sociodemographic variables in clinical trials, sociodemographic characteristics of study populations are underreported in randomised controlled trials and observational studies.<sup>9</sup> The most commonly reported sociodemographic variables include sex or gender identity (generally reported as binary variables) and race and ethnicity.<sup>9</sup> Establishing a set of CoDaV is one strategy to encourage robust data collection of sociodemographic variables perceived to influence health outcomes of critically ill adults. While core outcome sets are commonly developed using the Delphi consensus method, such as

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2023-082912 on 23 July 2024. Downloaded from <http://bmjopen.bmj.com/> on June 12, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES).

for delirium prevention and management<sup>10</sup> and for survivors of acute respiratory distress syndrome,<sup>11</sup> the modified Delphi process in this case will be used to identify core sociodemographic variables in critical care medicine.

### Aims and objective

We aim to develop an evidence-informed and knowledge-user-informed standardised catalogue of sociodemographic variables that would be reported, at minimum, in all Canadian-led ICU critical care clinical trials and observational studies.

### METHODS AND ANALYSIS

This protocol is registered online with the Open Science Framework (<https://osf.io/6da5m/>). Our study steering committee includes members of Equity, Diversity, and Inclusion and Patient and Family Partnership committees of the Canadian Critical Care Trials Group (CCCTG) reflecting diversity of age, gender identity, race and profession (past ICU patients and family members, critical care medicine researchers, clinicians and research co-ordinators).

### Scope

The scope of the sociodemographic core variables set will specifically apply as follows:

1. Health condition: critical illness requiring treatment in an ICU.
2. Population: adult patients ( $\geq 16$  years of age) admitted to an ICU.
3. Interventions: Any/no intervention/comparator (ie, for any study design).
4. Context: Primarily for adoption in Canadian critical care research and clinical trials evaluating the impact of SDoH. This includes, but is not restricted to, randomised controlled trials and observational cohort studies.

### Knowledge users

The participant panel will comprise representatives from four key knowledge user groups: former ICU patients and family members, critical care researchers, critical care clinicians and research co-ordinators. There is currently no standard on the optimal panel size to achieve consensus when using a modified Delphi technique.<sup>12</sup> We will aim to recruit approximately 20 participants representing each knowledge user group (80 participants in total). We will oversample for the first round based on an estimated attrition of 30% across rounds. Letters of invitation to participate will be emailed to relevant organisations (see below) for each knowledge user group. The letter will outline the study, anticipated timelines, estimated time commitment and request for consent to participate. We will use maximum variability sampling to ensure diversity in the cohort and selectively recruit based on demographics to fill any gaps.

A range of expertise is an important quality criterion for the development of CoDaVs. We will seek to include representatives from four key knowledge user groups who would be interested in the CoDaV. This includes the following groups:

1. Former ICU patients and family members: This group of knowledge users will include patients or families who have been admitted to an adult ICU. We will aim to recruit across equity deserving groups (eg, race, gender identity, economic strata). This will include, but is not be limited to, recruiting from the patient partners who are part of patient-centred and family-centred care or advisory committees or are engaged with research programmes led by CCCTG members. This group will be recruited by emailing CCCTG members to ask if their patient partner would like to participate in this research programme. A limitation of existing patient and family partnerships is a lack of diversity. We will seek new partnerships and try to engage at the bedside if we see there is an unfilled gap in representation across a certain group/strata. We will follow the recent Trial Forge Guidance to ensure recruitment of equity deserving groups, which includes the following: (1) ensure recruitment strategies do not limit participation in ways we do not intend (eg, widen the recruitment settings, translate study materials into the top five languages spoken in Canada); (2) ensure recruitment materials are developed with inclusion in mind; (3) ensure staff are culturally competent; and (4) build trusting partnerships with community organisations that work with ethnic minority groups. ICU patients and family partners are important knowledge users to engage in the development of this CoDaV because they can provide their perspective on what might be the important sociodemographic variables for patients and/or families. While it may be important to report ethnicity/race in studies to understand health disparities and potential differences in treatment outcomes, it will be imperative to ensure this group of knowledge users includes representation from equity deserving groups to avoid unintended consequences of the CoDaV such as reinforcing stereotypes, oversimplifying/misinterpreting findings, disregarding intersectionality, perpetuating health disparities and excluding other important factors.
2. Critical care researchers: A critical care researcher will be defined as someone who holds an academic or clinical appointment or is an individual who conducts research under the supervision of an independent researcher (eg, graduate student, postdoctoral fellow, post-health professional degree fellow) and has at least one publication related to adult critical care. This group will be recruited from national professional organisations relevant to critical care (CCCTG), through snowball sampling, and identified from a systematic search of publications of Canadian-led ICU trials in PubMed and clinicaltrials.gov over the last 10 years. Critical care researchers are important knowledge users.

ers to include in the development of this CoDaV for their expertise on critical care outcomes and research data collection.

3. Critical care clinicians: A critical care clinician will include clinicians (ie, physicians, registered nurses, registered respiratory therapists) and allied healthcare professionals (eg, physical therapists, occupational therapists, speech and language pathologists, social workers) who have a primary role in a Canadian adult ICU and a minimum of 2 years' experience post their first clinical degree. We will ensure representations from community and academic centres. Clinicians will be recruited from national professional organisations relevant to critical care (eg, Canadian Critical Care Society (CCCS), CCCTG, Canadian Association of Critical Care Nurses (CACCN), Canadian Society of Respiratory Therapists (CSRT)). Critical care clinicians are at the bedside and have experience of what sociodemographic variables may influence the health outcomes of critically ill adults and are engaged knowledge users in which data could be helpful to improve equity in the care of critically ill adults and their families.
4. Research co-ordinators: Research co-ordinators will include research professionals responsible for conducting clinical trials in a Canadian ICU (eg, research assistants, clinical research co-ordinators) and have at least 2 years of work experience in critical care. Research co-ordinators will be recruited through the Canadian Critical Care Research Coordinators Group (CCCRCG) and through snowball sampling from CCCTG-sponsored trials. Research co-ordinators are important to include because they are recruiting critically ill adult populations for participation in studies and recognise the barriers and facilitators to engaging minoritised participants. This often includes collecting relevant sociodemographic data for ICU studies.

## Information sources

A list of possible sociodemographic measures will be generated from six sources: (1) a published review of PubMed for critical care randomised trials (2010–2021)<sup>13</sup>; (2) a scoping review of demographic variables reported in Canadian-led studies conducted with a critically ill adult population, from January 2012; (3) a search of high impact critical care (*Intensive Care Medicine*, *American Journal of Respiratory Critical Care Medicine*, *Critical Care Medicine*, *Critical Care* and *CHEST*) and general medicine journal (*NEJM*, *The Lancet*, *JAMA*) websites for special issues relating to equity for sociodemographic variables associated with patient outcomes; (4) a search of the sociodemographic variables collected by the Canadian and provincial governments, institutions, organisations, CCCTG paediatric group (eg, universities, funding bodies) and selected international organisations (eg, National Institutes of Health, Athena Scientific Women's Academic Network); (5) variables mandated by high impact journals (eg, *Canadian Medical Association Journal (CMAJ)* and *NEJM*)<sup>14 15</sup>; and (6) the Canadian Institute for Health Information.<sup>16</sup> These will establish an initial comprehensive list of sociodemographic variables for round 1 of the modified Delphi consensus survey tailored to the Canadian setting.

We will conduct the scoping review using Arksey and O'Malley's methodological framework.<sup>17</sup> The scoping review will be reported using the Preferred Reporting Items for Systematic Review and Meta-Analyses extension for Scoping Reviews (online supplemental table 1).<sup>18</sup> We will search MEDLINE, Embase and CINAHL for Medical Subject Headings (MeSH) terms related to the setting (ICU) and region (ie, Canadian provinces and territories) from January 2012. Studies published prior to 2012 will be excluded, as this review aims to identify a comprehensive and contemporary list of variables and terms currently used in Canadian critical care studies. The

**Table 1** MEDLINE search strategy

Population	Canadian context
1. Critical care/ or Critical Illness/ or Intensive care units/ or ((intensive or critical or acute) adj2 (care* or therap*)).mp	6. Exp Canada/
2. (ICU* or ITU* or GICU* or CCU*).mp	7. (canad* or alberta or british columbia or colombie britannique or saskatchewan or manitoba or ontario or quebec or new brunswick or nouveau brunswick or nova scotia or nouvelle ecosse or prince edward island or ile du prince edward or PEI or newfoundland or terre neuve or labrador or nun\$vt\$ or territoires du nord ouest or northwest territories or nwt or yukon or ontario).mp.
3. ((critical* or severe or catastrophic* or acute*) adj2 (ill* or sick* or ail*)).mp	8. (edmonton or calgary or vancouver or victoria or prince george or kelowna or winnipeg or st* john?s or halifax or saint john or hamilton or waterloo or st catharines or sudbury or thunder bay or kingston or windsor or ottawa or toronto or mississauga or quebec city or montreal or trois?rivieres or sherbrooke or chicoutimi or moncton or saskatoon or western university).mp
4. ((critical* or severe or catastrophic* or acute*) adj2 (ill* or sick* or ail*)).mp	9. Or/6–8
5. Or/1–4	10. 5 and 9
	11. limit 10 to yr="2012 -Current"



**Table 2** Eligibility criteria

Inclusion criteria	Exclusion criteria
<ol style="list-style-type: none"> <li>1. Study design: Any original, published study including randomised controlled trials (RCTs) and quasi RCTs, observational cohort studies (prospective/retrospective) and biobanking studies (if stand alone and not associated with a clinical trial manuscript) where social determinants of health could be linked with outcomes.</li> <li>2. Language: Study is published in English or French.</li> <li>3. Population of interest: Study includes adult ICU patients.</li> <li>4. Country of origin: Study is Canadian led. The study can include sites from other countries but will be excluded unless the study is led or co-led by a Canadian investigative team (eg, corresponding author is Canadian).</li> <li>5. Outcome of interest: Study reports participant sociodemographic information (eg, age, sex, gender identity, race/ethnicity, educational attainment, employment, etc).</li> </ol>	<ol style="list-style-type: none"> <li>1. Ineligible study design: We will exclude study protocols that do not report results, cross-sectional survey studies, secondary analyses of a study, cross-sectional studies, systematic reviews, scoping reviews, narrative reviews, editorials and opinion pieces, letters to the editor and conference abstracts.</li> <li>2. Incorrect language: Study only available in a language other than English or French.</li> <li>3. Ineligible study population: Study did not enrol adult ICU patients.</li> <li>4. Incorrect country of origin: Study conducted solely outside of Canada.</li> <li>5. No mention of outcome of interest: Study does not report any participant's sociodemographic information.</li> </ol>

ICU, intensive care unit.

search strategy is adapted from a related study conducted by CCTG members (table 1).<sup>13</sup> The full search strategies are available in online supplemental tables 2–4.

The results of the search will be combined and deduplicated in Covidence systematic review software (Veritas Health Innovation, Melbourne, Victoria, Australia) for title/abstract and full-text screening. Prior to title/abstract screening, 25 randomly selected articles will be screened by researchers, applying the inclusion/exclusion criteria. Any disagreements will be resolved through discussion. Following this pilot test, two researchers will independently screen titles/abstracts in duplicate. Any title/abstract included by at least one researcher will advance to full-text screening. Studies will be included if they meet the following criteria: (1) any original, published study (eg, randomised controlled trials, prospective or retrospective cohort studies, where SDoH could be linked with outcomes); (2) published in English or French; (3) includes adult ICU patients; (4) led or co-led by a Canadian investigative team (eg, corresponding author is Canadian); and (5) reports participant demographics. Complete inclusion/exclusion criteria are included in table 2.

Two researchers will screen full-text articles independently and in duplicate. Disagreements on whether to include articles will be resolved through discussion or by a third reviewer. Reference lists of included articles will be reviewed to identify additional studies. One researcher will extract data, which will include study characteristics (title, year of publication, journal, funding source, study design, stated objective, study date range, sample size, number of participating centres, regulatory information) and demographic variables. A second researcher will review the data for accuracy and omissions. In keeping with the descriptive objectives of this scoping review, we have not planned any quantitative summary analyses and will not complete critical appraisals of included studies.<sup>19</sup>

Sociodemographic variables will be sorted into eight domains using the PROGRESS-Plus health equity framework.<sup>20</sup> PROGRESS includes social variables that influence health outcomes: Place of residence, Race/ethnicity/culture/


language, Occupation, Gender identity, Religion, Education, Socioeconomic status and Social capital. 'Plus' includes three additional categories: (1) personal characteristics associated with discrimination (eg, age, frailty, disability); (2) features of relationships (eg, relationships that impact an individual's ability to assert their autonomy and self-manage such as social capital (eg, marital status, community networks, professional networks)); and (3) time-dependent relationships (eg, times of transitions where an individual may face increased risks for poor health management such as discharge from hospital).

### Consensus process

We will conduct a modified Delphi consensus process for CoDaV development (flow of CoDaV development shown in figure 1). The modified Delphi consensus process will be informed by the RAND/University of California, Los Angeles (UCLA) appropriateness method<sup>21</sup> and reported according to the conducting and reporting Delphi studies reporting guidelines.<sup>22</sup> The modified Delphi consensus survey is a preferred method for CoDaV development because it is electronic (ie, panellists from across Canada can participate) and will allow participants to provide their anonymous views without influence from other panellists.<sup>12</sup>

We will use an online survey tool (Qualtrics, Provo, Utah, USA) to administer the survey. All surveys and participant-facing materials (ie, emails, informed consent forms, social media materials) will be developed and pilot-tested with eight individuals (two from each knowledge user group) prior to commencing the formal modified Delphi consensus survey to assess its flow, salience, acceptability and administrative ease.<sup>23</sup> Individuals will identify survey questions that are redundant, perceived as irrelevant or are poorly worded. Information obtained from pilot testing will be used to improve the survey. Surveys will be available in the five most commonly spoken languages in Canada after English/French: Mandarin, Punjabi, Yue (Cantonese), Spanish and Arabic.<sup>24</sup>

During round 1, we will collect self-reported demographic data (ie, pronouns, age, sex, gender identity, race and



**Figure 1** Description of the methods used to generate a set of core data variables for collection of sociodemographic measures in adult critical care trials. We will conduct a scoping review to generate an initial list of sociodemographic variables relevant to adult critical care research. This will be followed by three rounds of the modified Delphi consensus process to determine a core set of sociodemographic variables. This includes steps to rate (based on importance of individual variables) and rank (order or importance relative to other items in the same domain). All rounds will include panellists who are past intensive care unit (ICU) patients and family members, critical care medicine researchers, clinicians and research co-ordinators. Our methodology integrates knowledge translation by involving a diverse panel including past ICU patients and family members, critical care medicine researchers, clinicians and research co-ordinators. PROGRESS-Plus means social variables that influence health outcomes: Place of residence, Race/ethnicity/culture/language, Occupation, Gender identity, Religion, Education, Socioeconomic status and Social capital. 'Plus' includes three additional categories: (1) personal characteristics associated with discrimination (eg, age, frailty, disability); (2) features of relationships (eg, relationships that impact an individual's ability to assert their autonomy and self-manage such as social capital (eg, marital status, community networks, professional networks)); and (3) time-dependent relationships (eg, times of transitions where an individual may face increased risks for poor health management such as discharge from hospital).

ethnicity, visible minority, language, province of residence, role, duration of clinical and/or research experience, involvement in critical care research) to describe the panellists. We will then ask each panellist to rate each sociodemographic

variable (based on perceived importance for inclusion in the CoDaV) on a 9-point Likert scale (wherein 1–3: not important for inclusion; 4–6: important but not critical; 7–9: critical for inclusion). To avoid presentation bias, we

will randomise the sequence of presentation of the sociodemographic domains for each panellist. There will also be an opportunity for panellists to suggest additional sociodemographic variables or make comments using a free-text box after each domain. We will send three completion reminders at 1-week intervals.

We will define consensus for any sociodemographic factor a priori as a median score of 1–3 (not important for inclusion), 4–6 (important but not critical for inclusion) or 7–9 (critical for inclusion). Sociodemographic variables that are deemed not important for inclusion (ie, median score of 1–3) will be removed. Additional measures suggested during round 1 will be independently reviewed and coded by two study team members to ensure they represent new variables; any disagreements will be reviewed by a third study team member. The steering group will review and approve any additional variables and ensure the wording will be understandable by all panellists. We will email each panellist with a summary of the aggregated responses from all knowledge user groups 1 week prior to sending the round 2 survey.

During round 2, panellists will rate sociodemographic variables that did not meet consensus during round 1 and any new measures identified from round 1 on a scale from 1 to 9 (1–3: not important for inclusion; 4–6: important but not critical; 7–9: critical for inclusion). As with round 1, we will send three completion reminders at 1-week intervals. If there is substantial attrition (ie, loss of more than 30% of participants from a knowledge user group), we will recruit additional knowledge users for round 2. As with round 1, we will email each panellist with a summary of aggregated round 2 responses from all knowledge user groups 1 week prior to sending the round 3 survey.

Round 3 will be conducted for items that did not reach consensus from round 2. In addition, panellists will be asked to rank (based on order of importance relative to other items in the same PROGRESS-Plus domain) the items that reached consensus as critical for inclusion (ie, median score of 7–9 from rounds 1 and 2). Given that each PROGRESS-Plus domains will have an unequal number of items, items will be assessed to be a priority item if the item's mean ranking was  $\geq 1$  SD above the domain's mean ranking. For example, if a domain has a mean of 20.0 and a SD of 2.2, items with a mean score greater than 22.2 will be considered priority items.

### Maximising panel member participation

To minimise attrition, we will use strategies reported to be effective in related studies,<sup>25 26</sup> which include personalised invitations, collection of robust contact information (<http://www.improvelto.com/participant-contact-information-sheet>), regular reminders about survey completion (reminder emails, followed by telephone calls and text messages), summary of results (between Delphi rounds) and a unique identifier for each participant to monitor survey completion.

### Consensus meeting

Following completion of the modified Delphi, we will invite representatives from each knowledge user group from the Delphi panellists, members from each of the key critical care organisations in Canada (CCCTG, CCCS, CSRT, CCCRCG), representatives from a research ethics board, representatives from the Canadian Institutes of Health Research and editors from high impact Canadian medical journals (eg, *CMAJ*, *Canadian Journal of Anesthesia*) to hybrid (ie, in-person or virtual) consensus meeting. We will recruit a total of 40 panellists, ensuring they represent a diverse group of individuals and include panellists with lived experience or a strong equity, diversity, inclusion and indigeneity lens. The purpose of the consensus meeting is to: (1) reach consensus on the core sociodemographic measures set; (2) determine how each sociodemographic variable in the CoDaV should be measured (eg, level of granularity); and (3) discuss dissemination of the CoDaV, which includes accompanying guidance on *how* to use the CoDaV (to prevent aforementioned unintended consequences). Research team members with participant-facing roles in this meeting (eg, facilitating breakout sessions) will have completed trauma-informed care training per Substance Abuse and Mental Health Services Administration's trauma informed approach.<sup>27 28</sup> A report from this meeting will be written and published.

### Patient and public involvement

Past ICU patients were involved in the design, conduct, reporting and dissemination plans of our research.

### ETHICS AND DISSEMINATION

The current study protocol has received approval from the University of Calgary conjoint health research ethics board (REB22-1648). Participants will be recruited through professional groups, societies and organisations (CCCS, CCCTG, CCCRCG, CACCN, CSRT) and through social media posts (eg, Twitter). Participants will contact study team members in response to recruitment emails from professional societies and social media. Each participant will receive an information sheet on the objective of the study and expected time commitments and an informed consent form. Participation in Delphi surveys or the consensus meeting will imply consent to participate.

We will disseminate our findings through peer-reviewed and open access publications and presentations at national conferences. We will also create an infographic and lay summary and disseminate the CoDaV and its accompanying guidance on its use to key organisations for distribution among their networks and through social media posts (eg, X/Twitter, Reddit). We will engage with journal editors and funding bodies to promote awareness of the CoDaV.

### Author affiliations

<sup>1</sup>Department of Critical Care Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada



<sup>2</sup>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

<sup>3</sup>Department of Surgery, University of Toronto, Toronto, Ontario, Canada

<sup>4</sup>Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada

<sup>5</sup>Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada

<sup>6</sup>Department of Pediatrics, McGill University, Montreal, Québec, Canada

<sup>7</sup>Department of Paediatrics, University of British Columbia, Vancouver, British Columbia, Canada

<sup>8</sup>Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada

<sup>9</sup>Department of Medicine, Sinai Health System, Toronto, Ontario, Canada

<sup>10</sup>Department of Community Health Sciences & O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada

**X** Karla D Krewulak @KarlaKrewulak, Fatima Sheikh @fatima\_sheikh, Srinivas Murthy @srinimurthy99, Kristine Russell @kristinerussell and Kirsten Fiest @kmfiest

**Contributors** KDK, FS, AH, SMe and KF planned and designed the study. JCM, KEAB, SK, CM, SMu, KO'H and KR provided advice and guidance. KDK and FS drafted the manuscript with all authors reviewing and subsequently reviewing the final draft. KF is the guarantor.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods and analysis section for further details.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iDs

Karla D Krewulak <http://orcid.org/0000-0003-0300-4122>

Fatima Sheikh <http://orcid.org/0000-0002-1327-2203>

Katie O'Hearn <http://orcid.org/0000-0002-1149-2843>

Kirsten Fiest <http://orcid.org/0000-0002-7299-6594>

## REFERENCES

- Ahnquist J, Wamala SP, Lindstrom M. Social determinants of health--a question of social or economic capital? interaction effects of socioeconomic factors on health outcomes. *Soc Sci Med* 2012;74:930-9.
- Jayasinghe S. Social determinants of health inequalities: towards a theoretical perspective using systems science. *Int J Equity Health* 2015;14:71.
- Fowler RA, Sabur N, Li P, et al. Sex- and age-based differences in the delivery and outcomes of critical care. *CMAJ* 2007;177:1513-9.
- McGowan SK, Sarigiannis KA, Fox SC, et al. Racial disparities in ICU outcomes: A systematic review. *Crit Care Med* 2022;50:1-20.
- Calderón JL, Baker RS, Fabrega H, et al. An Ethno-medical perspective on research participation: a qualitative pilot study. *MedGenMed* 2006;8:23.
- Hussain-Gambles M, Atkin K, Leese B. Why ethnic minority groups are under-represented in clinical trials: a review of the literature. *Health Soc Care Community* 2004;12:382-8.
- Rochon PA, Mashari A, Cohen A, et al. The inclusion of minority groups in clinical trials: problems of under representation and under reporting of data. *Account Res* 2004;11:215-23.
- Thakur N, Lovinsky-Desir S, Appell D, et al. Enhancing recruitment and retention of minority populations for clinical research in pulmonary, critical care, and sleep medicine: an official American Thoracic society research statement. *Am J Respir Crit Care Med* 2021;204:e26-50.
- Orkin AM, Nicoll G, Persaud N, et al. Reporting of Sociodemographic variables in randomized clinical trials, 2014-2020. *JAMA Netw Open* 2021;4:e2110700.
- Rose L, Burry L, Agar M, et al. A core outcome set for research evaluating interventions to prevent and/or treat delirium in critically ill adults: an international consensus study (del-Cors). *Crit Care Med* 2021;49:1535-46.
- Needham DM, Sepulveda KA, Dinglas VD, et al. Core outcome measures for clinical research in acute respiratory failure survivors: an international modified Delphi consensus study. *Am J Respir Crit Care Med* 2017;196:1122-30.
- Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. *PLoS Med* 2011;8:e1000393.
- Li Y, Fiest K, Burns KEA, et al. Addressing Healthcare inequities in Canadian critical care through inclusive science: a pilot tool for standardized data collection. *Can J Anaesth* 2023;70:963-7.
- Stanbrook MB, Salami B. CMAJ's new guidance on the reporting of race and Ethnicity in research articles. *CMAJ* 2023;195:E236-8.
- Rubin E. Striving for diversity in research studies. *N Engl J Med* 2021;385:1429-30.
- Canadian Institute for Health Information. Guidance on the Use of Standards for Race-Based and Indigenous Identity Data Collection and Health Reporting in Canada, 2022. Available: <https://www.cihi.ca/sites/default/files/document/guidance-and-standards-for-race-based-and-indigenous-identity-data-en.pdf>
- Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005;8:19-32.
- Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for Scoping reviews (PRISMA-SCR): checklist and explanation. *Ann Intern Med* 2018;169:467-73.
- Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of Scoping reviews. *JBI Evid Implement* 2021;19:3-10.
- O'Neill J, Tabish H, Welch V, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially Stratifying factors to illuminate inequities in health. *J Clin Epidemiol* 2014;67:56-64.
- Fitch K, Bernstein SJ, Aguilar MD, et al. RAND/UCLA appropriateness method user's manual: RAND corporation, Santa Monica, CA. 2000.
- Jünger S, Payne SA, Brine J, et al. Guidance on conducting and reporting Delphi studies (CREDES) in palliative care: recommendations based on a methodological systematic review. *Palliat Med* 2017;31:684-706.
- Burns KEA, Duffett M, Kho ME, et al. A guide for the design and conduct of self-administered surveys of Clinicians. *CMAJ* 2008;179:245-52.
- Statistics Canada. Increasing diversity of languages, other than English or French, spoken at home 2021, Available: <https://www150.statcan.gc.ca/n1/pub/11-627-m/11-627-m2022051-eng.htm>
- Turnbull AE, Dinglas VD, Friedman LA, et al. A survey of Delphi panelists after core outcome set development revealed positive feedback and methods to facilitate panel member participation. *J Clin Epidemiol* 2018;102:99-106.
- Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a research methodology for nursing. *Int J Nurs Stud* 2001;38:195-200.
- Huang LN, Flatow R, Biggs T, et al. SAMHSA's Concept of Trauma and Guidance for a Trauma-Informed Approach Rockville, MD, 2014. Available: <https://store.samhsa.gov/sites/default/files/sma14-4884.pdf>
- Alberta Health Services. Traum training initiative. 2023. Available: <https://www.albertahealthservices.ca/info/page15526.aspx>

ONLINE SUPPLEMENT TO:

Core SocioDemographic data variables in ICU Trials (CoDe-IT): A protocol for generating core data variables using a Delphi consensus process

Table of Contents

Supplementary Table 1. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist..... 2

Supplementary Table 2. MEDLINE search strategy..... 5

Supplementary Table 3. EMBASE search strategy ..... 6

Supplementary Table 4. CINAHL search strategy ..... 7



**Supplementary Table 1.** Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
<b>TITLE</b>			
Title	1	Identify the report as a scoping review.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	5
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	6
<b>METHODS</b>			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	6
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	6
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	9
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	10, Table 1
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	10-11, Table 2
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	11-12

Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	11-12
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	12
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	12
<b>RESULTS</b>			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	NA
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	NA
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	NA
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	NA
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	NA
<b>DISCUSSION</b>			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	NA
Limitations	20	Discuss the limitations of the scoping review process.	4
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	NA
<b>FUNDING</b>			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	16

JB1 = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

\* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

*From:* Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–473. [doi: 10.7326/M18-0850](https://doi.org/10.7326/M18-0850).

**Supplementary Table 2.** MEDLINE search strategy

Study setting	Study region
1. Critical care/ or Critical Illness/ or Intensive care/ or Intensive care units/ or Intensive care units, pediatric/ 2. ((intensive or critical or acute) adj2 (care* or therap*)).tw,kf 3. (ICU* or GICU* or CCU* or PICU* or PCCU*).tw,kf 4. ((critical* or severe or catastrophic* or acute*) adj2 (ill* or sick* or ail*)).tw,kf 5. Or/1-4	6. exp canada/ 7. (canad* or alberta or british columbia or colombie britannique or saskatchewan or manitoba or ontario or quebec or new brunswick or nouveau brunswick or nova scotia or nouvelle ecosse or prince edward island or ile du prince edward or PEI or newfoundland or terre neuve or labrador or nun\$V\$t or territoires du nord ouest or northwest territories or nwt or yukon or ontario).mp. 8. (edmonton or calgary or vancouver or victoria or prince george or kelowna or winnipeg or st* john?s or halifax or saint john or hamilton or waterloo or st catharines or sudbury or thunder bay or kingston or windsor or ottawa or toronto or mississauga or quebec city or montreal or trois?rivi?res or sherbrooke or chicoutimi or moncton or saskatoon or western university).tw,kf. 9. ("Children's Hospital of Winnipeg" or Janeway Child Health Centre or IWK or "McMaster Children's Hospital" or "Children's Hospital at London Health" or "Children's Hospital of Eastern Ontario" or CHEO or Holland Bloorview Kids or Hospital for Sick Children or Hotel Dieu Hospital Child Development Centre or Centre de readaptation Marie Enfant or Sainte-Justine or "Montreal Children's Hospital" or Centre Mere-Enfant or "Jim Pattison Children's Hospital").mp. 10. Or/6-8 11. 5 and 9 12. limit 11 to yr="2012 -Current"



**Supplementary Table 3.** EMBASE search strategy

Study setting	Study region
1. intensive care/ or critical illness/ or intensive care unit/ or pediatric intensive care unit/	6. exp canada/
2. ((intensive or critical or acute) adj2 (care* or therap*)).mp	7. (canad* or alberta or british columbia or colombie britannique or saskatchewan or manitoba or ontario or quebec or new brunswick or nouveau brunswick or nova scotia or nouvelle ecosse or prince edward island or ile du prince edward or PEI or newfoundland or terre neuve or labrador or nun\$y\$st or territoires du nord ouest or northwest territories or nwt or yukon or ontario).mp.
3. (ICU* or GICU* or CCU* or PICU* or PCCU*).mp	8. (edmonton or calgary or vancouver or victoria or prince george or kelowna or winnipeg or st* john?s or halifax or saint john or hamilton or waterloo or st catharines or sudbury or thunder bay or kingston or windsor or ottawa or toronto or mississauga or quebec city or montreal or trois?rivers or sherbrooke or chicoutimi or moncton or saskatoon or western university).mp.
4. ((critical* or severe or catastrophic* or acute*) adj2 (ill* or sick* or ail*)).mp	9. ("Children's Hospital of Winnipeg" or Janeway Child Health Centre or IWK or "McMaster Children's Hospital" or "Children's Hospital at London Health" or "Children's Hospital of Eastern Ontario" or CHEO or Holland Bloorview Kids or Hospital for Sick Children or Hotel Dieu Hospital Child Development Centre or Centre de readaptation Marie Enfant or Sainte-Justine or "Montreal Children's Hospital" or Centre Mere-Enfant or "Jim Pattison Children's Hospital").mp.
5. Or/1-4	10. Or/6-8
	11. 5 and 9
	12. limit 10 to yr="2012 -Current"

**Supplementary Table 4.** CINAHL search strategy

Search ID #	Search terms
S1	MH critical care
S2	MH intensive care units+
S3	critical care
S4	intensive care
S5	ICU
S6	critical* ill*
S7	MH Canada+
S8	edmonton or calgary or vancouver or victoria or prince george or kelowna or winnipeg or st* john#s or halifax or saint john or hamilton or waterloo or st catharines or sudbury or thunder bay or kingston or windsor or ottawa or toronto or mississauga or quebec city or montreal or trois#rivers or sherbrooke or chicoutimi or moncton or saskatoon or western university
S9	canad* or alberta or british columbia or colombie britannique or saskatchewan or manitoba or ontario or quebec or new brunswick or nouveau brunswick or nova scotia or nouvelle ecosse or prince edward island or ile du prince edward or PEI or newfoundland or terre neuve or labrador or nun#v#t or territoires du nord ouest or northwest territories or nwt or yukon or ontario
S10	S1 or S2 or S3 or S4 or S5 or S6
S11	S7 or S8 or S9
S12	S10 and S11 ( <b>Limiters</b> - Publication Date: 20120101-20230231)